NCT02523976 2026-02-11
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
Clinical Trials
11 trialsNCT05433532 2024-04-25
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
Phase 2 Completed
NCT00287105 2023-05-24
ESPHALL
Rennes University Hospital
Phase 2 Completed
NCT01724879 2022-01-26
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
Goethe University
Phase 2 Completed
NCT01460498 2020-03-05
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01243489 2019-12-20
Crescendo
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 4 Completed
NCT00852566 2017-09-25
NordCML006
Norwegian University of Science and Technology
Phase 2 Completed
NCT01471067 2017-04-28
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00763763 2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00130195 2008-11-14
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
Japan Adult Leukemia Study Group
Phase 2 Completed
NCT00511303 2007-08-03
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
University of Bologna
Phase 2 Completed